By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kinex Pharmaceuticals 

1207 Delaware Avenue

Buffalo  New York  14209  U.S.A.
Phone: 716-332-6107 Fax: 716-332-6170


Company News
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-361 In A Phase 1 Clinical Study 12/24/2014 7:29:31 AM
Kinex Pharmaceuticals Appoints Chief Operating Officer 12/17/2014 9:12:10 AM
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Announce Preliminary Results From A Phase I Clinical Study (HM-OTE-103) With Oratecan® In Patients With Advanced Cancer 10/15/2014 7:56:26 AM
Kinex Pharmaceuticals Completes Acquisition Of QuaDPharma 9/9/2014 7:42:00 AM
Kinex Pharmaceuticals Announces Allowance Of The Investigational New Drug (IND) Application For KX2-391 Ointment By The United States FDA 7/24/2014 11:04:31 AM
Kinex Pharmaceuticals Appoints Mr. Michael Murphy To The Board Of Directors 7/1/2014 11:50:30 AM
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results On Oraxol® For Patients With Advanced Gastric Cancer From A Phase I/II Clinical Study 6/30/2014 9:05:33 AM
Kinex Pharmaceuticals Announces Key Additions To Clinical Leadership Team In Newly Formed Clinical Development Office In Cranford, New Jersey 5/13/2014 9:40:40 AM
Kinex Pharmaceuticals Receives FDA Allowance For Oratecan, An Oral Form Of Irinotecan With Enhanced Gastrointestinal Absorption, The Second U.S. IND Based On The Orascovery Technology Platform 5/5/2014 8:52:50 AM
Kinex Pharmaceuticals And Zenith Technology To Initiate Clinical Studies Of An Oral Form Of Paclitaxel (Oraxol) In New Zealand 3/20/2014 10:32:47 AM